Evidence map›Paper›PMID 32786014›Full record

ArticleBioEssays : news and reviews in molecular, cellular and developmental biology2020

Might SARS-CoV-2 Have Arisen via Serial Passage through an Animal Host or Cell Culture?: A potential explanation for much of the novel coronavirus' distinctive genome.

Karl Sirotkin, Dan Sirotkin

Abstract read
In one paragraph

Article in BioEssays : news and reviews in molecular, cellular and developmental biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Biosafety, biosecurity, and bioethics.Monash bioethics review · 2024
    Review
  3. Article
  4. Article
  5. There is no "origin" to SARS-CoV-2.Environmental research · 2022
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Should we discount the laboratory origin of COVID-19?Environmental chemistry letters · 2021
    Article
  16. Review
  17. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Karl SirotkinKarl Sirotkin LLC, 1301 Tadsworth Terrace, Lake Mary, FL, 32746, USA.ORCID 0000-0002-9685-0338
Dan SirotkinKarl Sirotkin LLC, 1301 Tadsworth Terrace, Lake Mary, FL, 32746, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite claims from prominent scientists that SARS-CoV-2 indubitably emerged naturally, the etiology of this novel coronavirus remains a pressing and open question: Without knowing the true nature of a disease, it is impossible for clinicians to appropriately shape their care, for policy-makers to correctly gauge the nature and extent of the threat, and for the public to appropriately modify their behavior. Unless the intermediate host necessary for completing a natural zoonotic jump is identified, the dual-use gain-of-function research practice of viral serial passage should be considered a viable route by which the novel coronavirus arose. The practice of serial passage mimics a natural zoonotic jump, and offers explanations for SARS-CoV-2's distinctive spike-protein region and its unexpectedly high affinity for angiotensin converting enzyme (ACE2), as well as the notable polybasic furin cleavage site within it. Additional molecular clues raise further questions, all of which warrant full investigation into the novel coronavirus's origins and a re-examination of the risks and rewards of dual-use gain-of-function research.

Indexed as

Amino Acid SequenceAngiotensin-Converting Enzyme 2AnimalsBetacoronavirusCoronavirus InfectionsCOVID-19Gain of Function MutationHumansPandemicsPeptidyl-Dipeptidase APneumonia, ViralProtein BindingSARS-CoV-2Serial PassageSpike Glycoprotein, CoronavirusZoonosesACE2 protein, humanAngiotensin-Converting Enzyme 2Peptidyl-Dipeptidase ASpike Glycoprotein, Coronavirusspike glycoprotein, SARS-CoVcoronavirusCOVID-19gain-of-functionintermediate hostpandemicSARS-CoV-2serial passagevirology

Identifiers

PMID32786014
PMCPMC7435492

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.